v3.26.1
SEGMENT INFORMATION
 6 Months Ended
Jun. 30, 2026
Segment Reporting [Abstract]  
SEGMENT INFORMATION

NOTE 11 – SEGMENT INFORMATION

 

Operating segments are defined as components of an entity for which separate financial information is available and that is regularly provided to the Chief Operating Decision Maker (“CODM”) in deciding how to allocate resources to an individual segment and in assessing performance. The Company conducted the business through two primary operating segments: NanoVibronix and ENvue. NanoVibronix derives revenues from selling its products directly to patients as well as through distributor agreements. ENvue derives revenues from selling its systems and nasoenteral tubes. Non-allocated administrative and other expenses are reflected in Corporate.

 

The Company’s Chief Executive Officer is the Company’s CODM. The CODM reviews financial information presented by operating segment in making operating decisions, allocating resources, and evaluating financial performance. The CODM allocates resources to and assesses the performance of each operating segment using information about the operating segment’s loss from operations.

 

Goodwill and Assets

 

   NanoVibronix   ENvue   Corporate   Total 
Balance sheet at June 30, 2026                    
Goodwill  $-   $29,082   $-   $29,082 
Assets  $2,206   $36,199   $-   $38,405 
                     
Balance sheet at December 31, 2025                    
Goodwill  $-   $29,082   $-   $29,082 
Assets  $1,924   $39,200   $-   $41,124 

 

Segment operating results

 

Six Months Ended June 30, 2026:  NanoVibronix   ENvue   Corporate   Total 
Revenues  $589   $303   $-   $892 
Cost of revenues   466    747    -    1,213 
Research and development   319    705    -    1,024 
Selling and marketing   775    1,149    -    1,924 
General and administrative   467    971    4,478    5,916 
Total operating loss  $(1,438)  $ (3,269)  $(4,478)  $(9,185)

 

Six Months Ended June 30, 2025:  NanoVibronix   ENvue   Corporate   Total 
Revenues  $1,367   $152   $-   $1,519 
Cost of revenues   875    310    -    1,185 
Research and development   1,184    383    -    1,567 
Selling and marketing   325    676    -    1,001 
General and administrative   1,231    802    1,561    3,594 
Total operating loss  $(2,248)  $(2,019)  $(1,561)  $(5,828)

 

Three Months Ended June 30, 2026:  NanoVibronix   ENvue   Corporate   Total 
Revenues  $55   $184   $-   $239 
Cost of revenues   77    428    -    505 
Research and development   279    231    -    510 
Selling and marketing   496    702    -    1,198 
General and administrative   87   328    3,085    3,500 
Total operating loss  $(884)  $ (1,505)  $(3,085)  $(5,474)

 

 

ENVUE MEDICAL, INC.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

(Amounts in thousands except share and per share data)

 

Three Months Ended June 30, 2025:  NanoVibronix   ENvue   Corporate   Total 
Revenues  $445   $49   $-   $494 
Cost of revenues   295    234    -    529 
Research and development   772    244    -    1,016 
Selling and marketing   180    493    -    673 
General and administrative   807    610    835    2,252 
Total operating loss  $(1,609)  $(1,532)  $(835)  $(3,976)

 

Geographic Information and Major Customer Data

 

The following is a summary of revenues within geographic areas:

 

   2026   2025   2026   2025 
   Three Months Ended June 30,   Six Months Ended June 30, 
   2026   2025   2026   2025 
United States  $233   $462   $723   $1,448 
Europe   6    8    169    17 
Australia/New Zealand   -    24    -    54 
Total  $239   $494   $892   $1,519 

 

Major Customer Data as a Percentage of Total Revenues

 

The following is a summary of revenues:

 

   2026   2025 
   Three Months Ended June 30, 
   2026   2025 
         
Customer F   24%   4%
Customer C   14%   34%
Customer D   -%   42%
Total   38%   80%

 

   2026   2025 
   Six Months Ended June 30, 
   2026   2025 
         
Customer A   21%   35%
Customer B   19%   1%
Customer C   14%   23%
Customer D   11%   25%
Total   65%   84%

 

 

ENVUE MEDICAL, INC.

Notes to the Interim Condensed Consolidated Financial Statements (Unaudited)

(Amounts in thousands except share and per share data)